• Patients undergoing myelosuppressive chemotherapy (CT) are at risk of neutropenia and subsequent infections.
• Separate nurse and patient surveys were conducted by the European Oncology Nursing Society (EONS) and PatientView.
-Nurses were identified by EONS.
-Patients with various types of cancer were identified by patient advocacy groups.
• Participants completed online questionnaires, provided in the local language and designed to assess:
-Whether patients are aware of the dangers of neutropenic infection.
-How much nurses tell patients about the risk of neutropenic infection.
-Whether patients at risk are offered prophylactic treatment to reduce neutropenia, FN and infection during CT.
• Percentages were calculated based on the number of responses to each question, or on the total number of respondents in the survey if more than one answer could be given. This represents an updated analysis since the submitted abstract. • These findings show that nurses recognise prevention of infection and FN as being important for achieving a successful outcome in patients undergoing CT.
• The patient survey relied on individual recall and differences in perceptions between the nurse and patient populations are partly attributable to differing treatment settings and countries. Also, there was a relatively low response rate to some questions. Nevertheless, results suggest that many patients do not understand, or are unaware of the risk of, developing neutropenia/FN infection and the potential impact of this on their CT and treatment outcome.
• Recommendations: Our results suggest that there may be a need for improvement in a number of areas of oncology care: -Communication between patients and healthcare professionals regarding CT-induced neutropenia/FN. Patients need to receive understandable and timely information. -Education/links for healthcare professionals looking after patients in the community.
-Provision of prophylaxis against neutropenia.
-Ensuring patient concordance with prophylaxis. -Access to oncologists/haematologists for patients who develop infection.
RESULTS
• The surveys were conducted between September 2009 and December 2009 and included:
-217 nurses ( Table 1 ) with an average caseload of 123-178 adult cancer patients per month, mostly within a national healthcare system (57%).
-473 patients (male 42%/female 58%; Table 2 ), mostly (59%) aged between 50-69 years.
• Patients in this survey were not the same patients being managed by the nurses in the survey. Thus, the geographical split and type of setting also differed between the two populations. 
Number

Awareness of Impact of Neutropenia and Infections
• When questioned about factors that may impact CT, 95% of nurses agreed that preventing infections and FN is extremely/very important in order to achieve a successful CT outcome: -97% agreed that infection or low WBC count can delay CT ( Figure 1A ). -73% felt that interruptions in CT may impact on effectiveness of treatment, while 68% said that treatment was less likely to be successful if there were changes in CT, such as reducing the dosage, delaying treatment or substituting drugs.
• However, many patients were unaware of the potential impact of delays and changes in their CT ( Figure 1B) and/or believed that they were not always given easy-to-understand information regarding cancer and infection (Figure 2 ).
• Almost all of the nurses said that they, or other health professionals in their practice, discussed with patients their personal risk of developing infection or FN (97%; Figure 3 ) and how to minimise the risk (99%).
• However, a substantial proportion of patients said they did not recall (19%), or were not told (29%) about the risk of developing FN and 21% said they were not told about the risk of infection. Only 58% of patients said that their personal risk of developing infection was discussed with them before starting CT.
Experience of Neutropenia and Infection and Impact on Treatment
• Nurses reported treating an average of 5-9 infections associated with FN per month (Figure 4 ) and virtually all (99%) reported seeing some of their patients hospitalised with fever, infection and/or FN within the past year.
• When asked about the impact of their latest infection on their CT, 203 patients responded to the question. 37% said that they had to have their CT delayed/changed as a result of neutropenia, infection or FN. 13% said they had to go to the emergency room and 57% said they were hospitalised.
Prevention and Management of Neutropenic Infections
• 89% of nurses said that local and/or national guidelines were in place for managing CT-induced neutropenia and 82% said that a local and/or national antibiotic policy was in place for managing neutropenia.
• 91% of nurses said in CT patients at risk, they preferred to give treatment to reduce FN and infections rather than treating an infection once it develops.
• 91% of the nurses reported use of antibiotics and/or granulocyte colony-stimulating factors (G-CSFs) to reduce FN in patients undergoing myelosuppressive CT (Figure 5A ), although most of them (85%) expressed some concern over patient concordance with FN prophylaxis.
• Less than 40% of the patients reported receiving antibiotics or medicines that increase WBC to reduce neutropenia and infections during their CT ( Figure 5B ).
• When asked which health professional was primarily responsible for treating their latest infection, less than 40% of patients said they were primarily treated by an oncologist (19%) or haematologist (14%). A significant proportion (13%) were treated by their GP/family doctor.
*Some patients indicated > 1 category The possibility of delays in your treatment [n = 318] The cause of delays in your treatment [n = 329] The medications used to prevent infection [n = 324] The medications used to increase white blood cell counts [n = 324] The potential that your dosage of chemotherapy may be reduced as a result of infection [n = 322] The issue of antibiotic resistance [n = 330] 
